Guest Post by Alex Berenson
Shares in Moderna and BioNTech are cratering as investors realize that demand for mRNA jabs for Covid and other respiratory illnesses will be near-zero going forward
It couldn’t have happened to a nicer bunch of medical billionaires.
Investors are voting on the failure of mRNA technology with their feet, fleeing the stocks of Moderna and BioNTech, the two companies that had the greatest wins on the mRNA Covid jabs.
In 2021 and 2022, Moderna and BioNTech rode Covid to tens of billions of dollars in profits. That gravy train is over.
Today, shares in Moderna and BioNTech fell below $100 a share for the first time since the jabs came to market in 2020, plunging almost 10 percent after BioNTech reported weak second-quarter sales and said it would reduce its planned research spending.